Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Fi

Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023...

Related Keywords

United States , Kwangdong , Ch Ungch Ong Bukto , South Korea , Cranbury , New Jersey , Hainan Province , Hainan , China , American , Carl Spana , Fosun Pharma , Palatin Technologies Inc , Kwangdong Pharmaceuticals , Securities Exchange , Prnewswire Palatin Technologies Inc , Dry Eye Disease , Data Expected Late , Calendar Year , Clinical Efficacy Across Multiple Signs , Dry Eye , Patient Safety , Ulcerative Colitis , Analysis Targeted , Expected First Half Calendar , Product Revenue Increased , Dispensed Increased , Quarter Fiscal Year Ended , Hypoactive Sexual Desire Disorder , Fiscal Year Ended June , New Jersey Net Operating Losses , Annual Report , Eastern Time , Melanocortin Receptor Agonists , Palatin Technologies , Securities Exchange Act , Private Securities , Months Ended June , Ended June , Seriesc Redeemable Convertible Preferred Stock , Nc ,